Robert Morgan

Mr. Morgan has been involved in drug development for over 30 years with experience in both large and small pharmaceutical companies covering multiple aspects of pre-and post-approval drug development. During his career, Mr. Morgan has submitted and maintained multiple INDs, NDAs, and international regulatory filings, including Orphan Drug Designation, Breakthrough Therapy Designation, and Emergency Use Authorization, and has been the functional leader for multinational clinical studies in the United States and abroad. He has held positions of increasing responsibility in pharmaceutical research and has worked in the Development Operations setting in multiple therapeutic areas for companies such as Verastem Oncology, MediVector, Ziopharm Oncology, DuPont Pharmaceuticals, Genzyme, Serono, and EPIX Pharmaceuticals. Mr. Morgan has a graduate degree in Medical Physics and is an attorney licensed in Massachusetts.